Jump to section
To make cardiovascular care easier for doctors and safer for patients.
HeartFlow was founded in 2007 and is a medical equipment manufacturer that uses CT-scanned 3D modeling to assess and analyze a patient's arteries. This noninvasive process can help assess the risks of heart disease and strategize the appropriate treatment.
HeartFlow has had a long history of awards and innovations. In 2021, it brought its technology to the NHS in England and in October 2022, introduced a plaque analysis service. As time has gone on, Heartflow has indicated that it is keeping up with technological advances and finding new ways to provide heart health services through them.
HeartFlow was successful in its IPO in June 2021, but hasn't had it completely straightforward since, with its merger with Longview Acquisitions reportedly called off due to unfavorable market conditions during early 2022. Nevertheless, the company has a strong position in the market and will be hoping to continue its product and revenue growth.
Steph
Company Specialist at Welcome to the Jungle
Apr 2023
$215m
SERIES F
Jun 2019
$65m
LATE VC
This company has top investors
Charles Taylor
(CSO)Previously Adjunct Professor at Institute for Computational Engineering and Sciences, Associate Professor of Bioengineering & Surgery at Stanford University.
Chris Zarins
(Senior VP)Previously President of Surgery at Stanford University.
Software Engineering
Finance, Legal & Compliance
Design
Other Engineering